Researchers discover new genes that promote brain cancer

Study identifies 2 novel oncogenes that cause childhood brain cancer when activated

2014-06-23

(Press-News.org) La Jolla, Calif., June 22, 2014, A new collaborative study carried out by researchers at Sanford-Burnham Medical Research Institute (Sanford-Burnham), UC San Diego, the German Cancer Research Center, the University of Heidelberg (Germany), and 33 other research institutions has identified two oncogenes, called GFI1 and GFI1B, that drive the development of medulloblastoma, the most common malignant brain tumor in children. The findings, published June 22 in Nature, suggest that GFI1 and GFI1B are worthy gene candidates for molecular-targeted therapy. "Using state-of-the-art technologies to survey the genomes of tumors derived from medulloblastoma patients, we have identified new oncogenes that drive the growth of a considerable proportion of Group 3 and 4 medulloblastomas. Patients with Group 3 and 4 tumors have the poorest outcomes and the fewest therapeutic options of all medulloblastoma patients," said Robert Wechsler-Reya, Ph.D., director of the Tumor Initiation and Maintenance Program at Sanford-Burnham, and co-senior author of the paper. Current therapy for patients with medulloblastoma includes surgery, radiation, and high-dose chemotherapy. Although these therapies have a significant impact on tumor growth, many children ultimately relapse and die of the disease. Moreover, survivors suffer profound long-term side effects—including cognitive deficits and increased susceptibility to other cancers—as a result of the aggressive treatment. "Going forward, we expect that the genetic profiles of medulloblastoma tumors will lead to markers that allow us to adjust a patient's therapy to target the genes that are actually driving the growth of the tumor. Our findings are promising in that they may ultimately lead to genetically informed clinical trials of new agents that target the genetic variations we discovered," said Wechsler-Reya. Hijacking gene enhancers The study also revealed how the oncogenes—inactive in normal healthy brains—become activated in medulloblastoma by "hijacking" unrelated DNA elements called "enhancers." Enhancers are short regions of DNA that activate genes, and there are hundreds of thousands of them in the human genome. "Chromosome rearrangements that merge oncogenes with enhancers have been observed in lymphoid cancers, such as non-Hodgkin's lymphoma," said Wechsler-Reya. "But this is the first report of this phenomenon in brain tumors." Chromosome rearrangements occur when segments of the DNA double helix are deleted, amplified, or swap positions—disrupting the normal order and sequence of genes. "Gene rearrangements that activate oncogenes have broad-reaching implications for cancer genomics," said Paul Northcott, Ph.D., senior researcher at the German Cancer Research Center and co-first author of the study. "It will be interesting to re-examine the genomes of other cancers using today's sophisticated analytical tools to see if the enhancer hijacking process of activating oncogenes is broader than we currently understand. "Moreover, these rearrangements leading to GFI1 and GFI1B activation open up promising new avenues for the treatment of medulloblastoma patients, as novel therapies specifically targeting enhancers are currently making their way into clinical trials for other cancers. Targeting enhancers bypasses some of the caveats associated with the direct targeting of oncogenes themselves, which can be notoriously difficult to inhibit," added Northcott.

INFORMATION: This work was principally supported by the National Cancer Institute (R01 CA122759), the California Institute for Regenerative Medicine (CIRM LA1-01747), and the PedBrain Tumor Project contributing to the International Cancer Genome Consortium, funded by the German Cancer Aid (109252) and by the German Federal Ministry of Education and Research (BMBF, grants 01KU1201A, MedSys 0315416C, and NGFNplus 01GS0883).

About Sanford-Burnham Medical Research Institute Sanford-Burnham Medical Research Institute is dedicated to discovering the fundamental molecular causes of disease and devising the innovative therapies of tomorrow. Sanford-Burnham takes a collaborative approach to medical research with major programs in cancer, neurodegeneration and stem cells, diabetes, and infectious, inflammatory, and childhood diseases. The Institute is recognized for its National Cancer Institute-designated Cancer Center and expertise in drug discovery technologies. Sanford-Burnham is a nonprofit, independent institute that employs 1,200 scientists and staff in San Diego (La Jolla), Calif., and Orlando (Lake Nona), Fla. For more information, visit us at sanfordburnham.org.

Sanford-Burnham can also be found on Facebook at facebook.com/sanfordburnham and on Twitter @sanfordburnham.

ELSE PRESS RELEASES FROM THIS DATE:

Vitamin D can lower weight, blood sugar via the brain

2014-06-23

CHICAGO, IL—Women with type 2 diabetes and high cholesterol are less likely than their male peers to reach treatment goals to lower their "bad" cholesterol, or low-density lipoprotein (LDL) cholesterol, despite access to cholesterol-lowering medication, a Canadian study finds. The results were presented on Saturday at the joint meeting of the International Society of Endocrinology and the Endocrine Society: ICE/ENDO 2014 in Chicago. Although other research has shown a similar gender gap in reduction of LDL cholesterol among adults with diabetes, the new study found that ...

Low number of taste buds linked to older age, higher fasting blood sugar

2014-06-23

CHICAGO, IL—A study finds that the number of taste buds we have on our tongue decreases as we get older, and that the lower the number of taste buds, the more likely for fasting blood glucose (sugar) levels to be higher than normal. The results were presented Sunday at the joint meeting of the International Society of Endocrinology and the Endocrine Society: ICE/ENDO 2014 in Chicago. Because high fasting blood sugar level is a main characteristic of diabetes, the study findings suggest that the number of taste buds plays a role in glucose metabolism—how the body uses ...

Growth hormone defect may protect against diabetes, cancer in unique ecuador population

2014-06-23

CHICAGO, IL — People who lack growth hormone (GH) receptors also appear to have marked insulin sensitivity that prevents them from developing diabetes and lowers their risk for cancer, despite their increased percentage of body fat, new research finds. The results were presented Sunday, June 22, at ICE/ENDO 2014, the joint meeting of the International Society of Endocrinology and the Endocrine Society in Chicago. "We have shown that people who, due to a genetic defect, are unable to respond to growth hormone have an increased sensitivity to insulin that safeguards them ...

Hypothyroidism may lead to impaired driving

2014-06-23

CHICAGO, IL — People with significant hypothyroidism can experience impaired driving similar to those who are driving when intoxicated by alcohol, a new study finds. The results were presented Sunday at the joint meeting of the International Society of Endocrinology and the Endocrine Society: ICE/ENDO 2014 in Chicago. Hypothyroidism, insufficient thyroid hormone, is very common and has been known to cause impairment of many bodily functions, including brain function. Until now, studies have not sufficiently explored the extent of brain impairment and whether hypothyroid ...

High blood sugar causes brain changes that raise depression risk

2014-06-23

CHICAGO, IL — Researchers have found a possible biological reason why people with diabetes are prone to depression. A new study shows that high blood glucose (sugar) levels in patients with Type 1 diabetes increase the levels of a brain neurotransmitter associated with depression, and alter the connections between regions of the brain that control emotions. The results will be presented Sunday at the joint meeting of the International Society of Endocrinology and the Endocrine Society: ICE/ENDO 2014 in Chicago. "It was traditionally thought that patients with Type 1 or ...

Soy supplements appear to be safe, beneficial in diabetic men

2014-06-23

CHICAGO, IL—Soy protein supplements, which contain natural estrogens, do not reduce testosterone levels in men with Type 2 diabetes who already have borderline-low testosterone, according to a new study. The results were presented Saturday at the joint meeting of the International Society of Endocrinology and the Endocrine Society: ICE/ENDO 2014 in Chicago. "Because soy contains phytoestrogens that are similar to the female hormone estrogen, it was not known whether consumption of soy could reduce testosterone levels in men with Type 2 diabetes, who are at increased risk ...

Most people with type 1 diabetes do not use diabetes devices to get long-term data

2014-06-23

CHICAGO, IL—Almost 70 percent of adults with Type 1 diabetes never use their blood glucose self-monitoring devices or insulin pumps to download historical data about their blood sugar levels and insulin doses—information that likely would help them manage their disease better. These new survey results, which were presented Sunday at the joint meeting of the International Society of Endocrinology and the Endocrine Society: ICE/ENDO 2014 in Chicago, also show that only 12 percent of patients regularly review their past glucose and insulin pump data at home. "This research ...

BPA exposure during fetal development raises risk of precancerous prostate lesions

2014-06-23

CHICAGO, IL — A new study has found for the first time that the endocrine-disrupting chemical bisphenol A (BPA) reprograms the developing prostate, making the gland more susceptible to precancerous lesions and other diseases later in a man's life. The results will be reported Sunday at the joint meeting of the International Society of Endocrinology and the Endocrine Society: ICE/ENDO 2014 in Chicago. "By using two novel models of human prostate development involving embryonic stem cells, this study is the first to show that low doses of BPA can actually reprogram human ...

Denosumab treatment for postmenopausal osteoporosis increases bone density

2014-06-23

CHICAGO, IL — Postmenopausal women with osteoporosis who take denosumab long-term have increased bone density, sustained low rate of fractures, and a favorable benefit/risk profile, a new multinational study finds. The results were presented Sunday, June 22, at ICE/ENDO 2014, the joint meeting of the International Society of Endocrinology and the Endocrine Society in Chicago. "This study provides reassurance to physicians and their patients that long-term treatment with denosumab for at least 8 years leads to significant increases in bone density and is safe for appropriately ...

Empagliflozin lowers high blood pressure and blood sugar in diabetics

2014-06-23

CHICAGO, IL — An investigational drug to treat Type 2 diabetes, empagliflozin, lowers blood pressure in patients with Type 2 diabetes and hypertension (high blood pressure), a new study finds. The results were presented Sunday in a late-breaking abstract at the joint meeting of the International Society of Endocrinology and The Endocrine Society: ICE/ENDO 2014 in Chicago. This improvement in blood pressure reportedly was accompanied by a reduction in blood glucose (sugar) levels after 12 weeks of treatment with the drug, which is under development by Germany-based Boehringer ...

LAST 30 PRESS RELEASES:

Scientists design solar-responsive biochar that accelerates environmental cleanup

Construction of a localized immune niche via supramolecular hydrogel vaccine to elicit durable and enhanced immunity against infectious diseases

Deep learning-based discovery of tetrahydrocarbazoles as broad-spectrum antitumor agents and click-activated strategy for targeted cancer therapy

DHL-11, a novel prieurianin-type limonoid isolated from Munronia henryi, targeting IMPDH2 to inhibit triple-negative breast cancer

Discovery of SARS-CoV-2 PLpro inhibitors and RIPK1 inhibitors with synergistic antiviral efficacy in a mouse COVID-19 model

Neg-entropy is the true drug target for chronic diseases

Oxygen-boosted dual-section microneedle patch for enhanced drug penetration and improved photodynamic and anti-inflammatory therapy in psoriasis

Around the world, children’s cooperative behaviors and norms converge toward community-specific norms in middle childhood, Boston College researchers report